COMMUNIQUÉS West-GlobeNewswire

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
19/03/2026
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026
19/03/2026
ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
19/03/2026
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile [...]
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
19/03/2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
Trading in GN Store Nord shares by board members, executives and associated persons
19/03/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
19/03/2026
Company Announcement COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to constitute itself. Ms. [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
19/03/2026
CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
New partnership to fast-track Canadian health technology from innovation to patient care
19/03/2026
AIM Institute and CAN Health Network join forces to help Canadian solutions reach clinicians and patients faster NEW WESTMINSTER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Royal Columbian Hospital Foundation’ [...]
Backpage Sex Trafficking Survivors Break Silence, Demand Investigation of Uncharged Enablers as Compensation Deadline Approaches
19/03/2026
WASHINGTON, March 19, 2026 (GLOBE NEWSWIRE) -- With a March 31st court-imposed deadline approaching for Backpage sex trafficking victims to seek financial compensation, a group of approximately 20 survivors is publicly [...]
SK pharmteco réaffirme sa stratégie à trois unités d’activité et renforce son pôle mondial de thérapie génique grâce à un engagement de financement
19/03/2026
RANCHO CORDOVA, Californie, 19 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé aujourd’hui un engagement de financement significatif visant à soutenir des initiatives stratégiques au sein de son activité de [...]
The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function
19/03/2026
The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the [...]
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
19/03/2026
Wegovy ® HD demonstrated a mean weight loss of 20.7% 1 , and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial First US FDA approval of a GLP-1 treatment under the Commissioner’s [...]
NMDP Celebrates Bipartisan Senate Introduction of Life-saving Blood Stem Cell Therapeutic and Research Reauthorization Act
19/03/2026
The C.W. Bill Young Cell Transplantation Program Has Impacted Nearly 150,000 Lives Since Inception, a 33% Increase in the Last Five Years MINNEAPOLIS, March 19, 2026 (GLOBE NEWSWIRE) -- NMDP SM , the nonprofit [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
19/03/2026
SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong [...]
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
19/03/2026
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
19/03/2026
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX [...]
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client
19/03/2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
19/03/2026
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading [...]

Pages